Diagnostics / NGAL ELISA


Cat.No. KIT 036

An ELISA for the  in vitro  determination of human NGAL in urine, serum, plasma, tissue extracts or culture media.

Target Human NGAL (Neutrophil Gelatinase-Associated Lipocalin)
Sample Type Human urine and plasma
Cross reaction None
Numbers of tests 96 wells - 40 test in duplicate
Sample vol needed 10 µl
Dilution guideline 1/500 (Urine from healthy subjects)
Assay range 10-1000 pg/mL
Limit of Detection 4 pg/mL
Assay time <4 hours
Result type Quantitative (pg/mL)
Application For in vitro diagnostic use in the European Union and Canada. RUO - Research Use Only in all other markets.

Kit features

*Not available in the USA for in vitro diagnostic use. 

*For in vitro diagnostic use in the European Union, Canada and Iran. For research use only in all other terrirories.

NGAL is a new early biomarker for diagnosing acute kidney injury (AKI)

Under normal conditions, NGAL levels are low in urine and plasma, but they rise sharply from basal levels in response to kidney injury to reach diagnostic levels within a very short time - as much as 24 hours or more before any significant rise in serum creatinine.

Clinical application

Measuring NGAL in urine or plasma gives you information on AKI status that you need for rapid decision making e.g. in the following settings -

  • Intensive care - monitoring
  • Emergency room - triage tool
  • Cardiopulmonary bypass surgey - monitoring
  • Renal transplantation - predictive evaluation
  • Intravenous contrast agents - assessing nephrotoxicity

What is NGAL?

NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2, siderocalin) is a small protein expressed in neutrophils and certain epithelia, including the renal tubules. Renal expression of NGAL is dramatically increased in kidney injury from a variety of causes, and NGAL is released into both urine and plasma. NGAL levels rise within 2 hours of the insult, making NGAL an early and sensitive biomarker of kidney injury.

Method patented/patent pending in selected countries.

For further patent information please click here